{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG000","lowerLimit":"19.8","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Time from first dose to death due to any cause in the LGG cohort. Confidence Intervals were estimated using the Brookmeyer Crowley method. If a patient was not known to have died at the time of analysis cut-off, OS was censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"}],"paramType":"MEDIAN","populationDescription":"All participants on the HGG cohort to whom study treatment had been assigned and who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 5.1 years","title":"HGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}